Skip to main content
Log in

Inhaled corticosteroids or montelukast as the preferred primary long-term treatment for pediatric asthma?

  • Review
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

An Erratum to this article was published on 15 April 2008

Abstract

According to current guidelines, inhaled corticosteroids (ICS) are the preferred primary long-term treatment for asthmatic children of all age groups, but leukotriene receptor antagonists can be considered to be an alternative treatment for mild persistent asthma. In this article, all randomized double-blind efficacy studies comparing the long-term (>4-week) treatment using a leukotriene receptor antagonist with an inhaled corticosteroid in asthmatic children were critically reviewed. In school-aged children, five reports with an adequate study design were available. All of these studies compared montelukast with inhaled fluticasone. The meta-analysis of the two main outcome measures, forced expiratory volume in 1 s (weighted mean difference, 4.6% predicted, 95% confidence interval: 3.5–5.5) and asthma control days (respectively, 5.6%, 4.3–6.9) demonstrated the superiority of fluticasone over montelukast. Many other clinical and pulmonary outcomes also consistently showed that low-dose inhaled fluticasone was more effective than montelukast in the long-term management of mild to moderate persistent asthma. A more favorable response to fluticasone over montelukast was associated with more severe disease or markers of allergic inflammation. About a quarter of patients benefited more from montelukast than fluticasone. In children under school age, no comparative studies were available. However, long-term montelukast treatment was found to be effective in placebo-controlled studies in asthmatic children aged >2 years. These findings support the present international recommendations for ICS as the preferred first-line controller therapy for mild to moderate persistent childhood asthma. If montelukast is selected as a monotherapy and asthma is not adequately controlled within 4–6 weeks, the treatment should be discontinued and the preferred medication initiated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. van Adelsberg J, Moy J, Wei LX, Tozzi CA, Knorr B, Reiss TF (2005) Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthma. Curr Med Res Opin 21:971–979

    Article  PubMed  CAS  Google Scholar 

  2. Bisgaard H, Nielsen KG (2000) Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children. Am J Respir Crit Care Med 162:187–190

    PubMed  CAS  Google Scholar 

  3. Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L, Menten J, Tozzi CA, Polos P (2005) Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 171:315–322

    Article  PubMed  Google Scholar 

  4. Buchvald F, Bisgaard H (2003) Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide. Ann Allergy Asthma Immunol 91:309–313

    PubMed  CAS  Google Scholar 

  5. Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, Kuderer NM, Lyman GH (2000) The uncertainty principle and industry-sponsored research. Lancet 356:635–638

    Article  PubMed  CAS  Google Scholar 

  6. Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P (2005) Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 116:360–369

    Article  PubMed  Google Scholar 

  7. Ghiro L, Zanconato S, Rampon O, Piovan V, Pasquale MF, Baraldi E (2002) Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children. Eur Respir J 20:630–634

    Article  PubMed  CAS  Google Scholar 

  8. Goodman DC (2005) When an asthma drug has an inferiority complex: a noninferiority trial. Pediatrics 116:493–495

    Article  PubMed  Google Scholar 

  9. Johnston NW, Mandhane PJ, Dai J, Duncan JM, Greene JM, Lambert K, Sears MR (2007) Montelukast added to usual therapy during the September epidemic of asthma exacerbations in children. J Allergy Clin Immunol 119:S4

    Article  Google Scholar 

  10. Kemp JP, Dockhorn RJ, Shapiro GG, Nguyen HH, Reiss TF, Seidenberg BC, Knorr B (1998) Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 133:424–428

    Article  PubMed  CAS  Google Scholar 

  11. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, Becker A (1998) Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 279:1181–1186

    Article  PubMed  CAS  Google Scholar 

  12. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, Michele TM, Reiss TF, Nguyen HH, Bratton DL (2001) Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 108:E48

    Article  PubMed  CAS  Google Scholar 

  13. Melo RE, Solé D, Naspitz CK (2003) Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and late-phase responses. J Allergy Clin Immunol 111:301–307

    Article  PubMed  CAS  Google Scholar 

  14. Meyer KA, Arduino JM, Santanello NC, Knorr BA, Bisgaard H (2003) Response to montelukast among subgroups of children aged 2 to 14 years with asthma. J Allergy Clin Immunol 111:757–762

    Article  PubMed  CAS  Google Scholar 

  15. National Heart, Lung, and Blood Institute (2007) Expert Panel Report 3: guidelines for the diagnosis and management of asthma. Full report, available online at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf

  16. Ostrom NK, Decotiis BA, Lincourt WR, Edwards LD, Hanson KM, Carranza Rosenzweig JR, Crim C (2005) Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr 147:213–220

    Article  PubMed  CAS  Google Scholar 

  17. Phipatanakul W, Greene C, Downes SJ, Cronin B, Eller TJ, Schneider LC, Irani AM (2003) Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann Allergy Asthma Immunol 91:49–54

    Article  PubMed  CAS  Google Scholar 

  18. Scottish Intercollegiate Guidelines Network (SIGN) The British Thoracic Society (2007) British guideline on the management of asthma. Available online at http://www.sign.ac.uk/guidelines/fulltext/63/index.html

  19. Sorkness CA, Lemanske RF Jr, Mauger DT, Boehmer SJ, Chinchilli VM, Martinez FD, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, Bloomberg GR, Covar RA, Guilbert TW, Heldt G, Larsen G, Mellon MH, Morgan WJ, Moss MH, Spahn JD, Taussig LM; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute (2007) Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 119:64–72

    Article  PubMed  Google Scholar 

  20. Spahn JD, Covar RA, Jain N, Gleason M, Shimamoto R, Szefler SJ, Gelfand EW (2006) Effect of montelukast on peripheral airflow obstruction in children with asthma. Ann Allergy Asthma Immunol 96:541–549

    PubMed  CAS  Google Scholar 

  21. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, Zeiger RS, Larsen G, Spahn JD, Bacharier LB, Bloomberg GR, Guilbert TW, Heldt G, Morgan WJ, Moss MH, Sorkness CA, Taussig LM (2005) Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 115:233–242

    Article  PubMed  CAS  Google Scholar 

  22. Zeiger RS, Szefler SJ, Phillips BR, Schatz M, Martinez FD, Chinchilli VM, Lemanske RF Jr, Strunk RC, Larsen G, Spahn JD, Bacharier LB, Bloomberg GR, Guilbert TW, Heldt G, Morgan WJ, Moss MH, Sorkness CA, Taussig LM; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute (2006) Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 117:45–52

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The author wishes to thank statistician Jaakko Matomäki, MSc, for performing the meta-analyses.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tuomas Jartti.

Additional information

Supported by the Academy of Finland.

The author has no conflict of interest in connection with this paper.

An erratum to this article can be found at http://dx.doi.org/10.1007/s00431-008-0699-9

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jartti, T. Inhaled corticosteroids or montelukast as the preferred primary long-term treatment for pediatric asthma?. Eur J Pediatr 167, 731–736 (2008). https://doi.org/10.1007/s00431-007-0644-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00431-007-0644-3

Keywords

Navigation